Literature DB >> 7587042

Econotherapeutics.

M K Roark1, W E Reed.   

Abstract

A program that represents the efforts of a hospital pharmacy management company to control drug costs is described. The program, Econotherapeutics, was developed in response to a changed health care reimbursement system that focused on the costs of products rather than the revenue generated by these products. For antimicrobial agents, a hospital-specific antibiogram is used to encourage cost-effective prescribing. A pharmacist intervention program, medical staff presentations, drug usage evaluation, management systems, and educational programs for pharmacists are all essential parts of the program. Centralized data gathering has allowed cost comparison of specific antimicrobial agents so that differences between variable cost estimates and costs based on actual use can be evaluated. Actual dose and dosage interval were used to calculate average cost per treatment day in a 121-hospital sample. Our cost data support the choice of cefotaxime over ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587042     DOI: 10.1016/0732-8893(95)00078-o

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors:  J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial.

Authors:  Shawn D St Peter; Kuojen Tsao; Troy L Spilde; George W Holcomb; Susan W Sharp; J Patrick Murphy; Charles L Snyder; Ronald J Sharp; Walter S Andrews; Daniel J Ostlie
Journal:  J Pediatr Surg       Date:  2008-06       Impact factor: 2.545

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.